Sex-based differences in chronic heart failure: a systematic review and meta-analysis of randomized controlled trials
Open Access
- 15 October 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Abstract
Background: Sex-based disparities in patient enrolment and treatment effects in heart failure (HF) randomized controlled trials (RCTs) have been reported. We aim to systematically analyse sex-based enrolment and treatment effect differences in HF RCTs over time. Methods: RCTs enrolling patients with chronic HF were systematically searched on PubMed-MEDLINE. Eligible trials included pharmacological or device-based interventions with a hard primary endpoint (mortality and hospitalization) and reporting enrolment of women. Sex-specific treatment effects (hazard ratio [HR] or risk ratio [RR]) were extracted. Meta-analyses were performed using random-effects models, and pre-specified subgroup analyses were performed. Results: A total of 56 RCTs (39 drug, 17 device) were included. The pooled proportion of women enrolment was 27.0% (95% confidence interval [CI]: 22.0%–32.4%) in drug trials and 25.3% (95% CI: 21.0%–29.9%) in device trials. Women were more underrepresented in HF with reduced ejection fraction (HFrEF) than in HF with preserved EF (HFpEF) trials (21.0% vs 49.6%, P < .001). Among drug trials reporting sex-specific effects, the pooled sex interaction for RCTs reporting HR was 0.94 (95%CI 0.89–1.01) and RR was 0.81 (95% CI 0.68–0.96), suggesting potentially greater benefit for women. No interaction was observed between HFrEF and HFpEF trials (HR: P = 0.44; RR: P = .95). The pooled interaction estimate on event counts was 0.90 (95%CI 0.84–0.96). For devices, the pooled sex interaction for RCTs reporting HR was 1.05 (95% CI 0.90–1.22) and RR was 0.68 (95% CI 0.50–0.93). Conclusion: Women remain underrepresented in HF RCTs. Sex-stratified analyses suggest a potentially greater relative benefit of drug intervention in women, which might inform future RCTs. Further studies are required to investigate the mechanisms of these differences.Keywords
This publication has 29 references indexed in Scilit:
- Sex Differences in Dilated CardiomyopathyJACC, 2025
- Arrhythmic Risk Stratification of Carriers of Filamin C Truncating VariantsJAMA Cardiology, 2025
- Differences in Presentation, Diagnosis and Management of Heart Failure in Women. A Scientific Statement of the Heart Failure Association of the ESCEuropean Journal of Heart Failure, 2024
- Sex-Based Differences in Heart FailureJACC, 2022
- A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection FractionJACC: Heart Failure, 2022
- Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic reviewEuropean Journal of Heart Failure, 2020
- Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort studyThe Lancet, 2019
- Pathophysiology, Diagnosis and Management of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum CardiomyopathyEuropean Journal of Heart Failure, 2019
- Sex-Based Differences in Heart Failure Across the Ejection Fraction SpectrumEuropean Journal of Heart Failure, 2019
- Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and WomenJACC, 2019